Related Experiment Video
Updated: Feb 23, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
Influence of the MIF polymorphism -173G > C on Turkish postmenopausal women with osteoporosis
A Z Ozsoy1, N Karakus2, S Tural3
1Department of Obstetrics and Gynecology, Gaziosmanpasa University, Faculty of Medicine, Tokat, Turkey.
Background:
MIF, a proinflammatory cytokine, contributes to the pathogenesis of acute, chronic, and autoimmune inflammatory disorders and balances the suppressive effect of glucocorticoids on the immune system. There is an interaction between bone metabolism and the immune system via the production of cytokines. We aimed to analyze the relationship between the MIF gene -173G > C promoter polymorphism and osteoporosis.
Methods:
In this case-control study performed in a university hospital, 286 samples (136 women with osteoporosis and 150 healthy age-matched controls) participated. The polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) assay was used to genotype the MIF gene polymorphism. The alleles and genotypes frequencies of patients and controls were compared using the χ2 test.
Results:
The genotype frequencies of MIF gene -173G > C polymorphism showed statistically significant differences between patients and controls (p = 0.038). Also, the subjects carrying the variant C allele in the MIF -173 position were at significantly higher risk of osteoporosis than subjects carrying the wild-type G allele (p = 0.009, odds ratio 1.7, 95% confidence interval 1.1-2.6).
Conclusion:
Our study suggested a strong association between MIF gene -173G > C polymorphism and osteoporosis in a Turkish population.
More Related Videos
07:51Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase